Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Times Interest Earned (2021 - 2025)

Historic Times Interest Earned for Autolus Therapeutics (AUTL) over the last 5 years, with Q3 2025 value amounting to -$6.81.

  • Autolus Therapeutics' Times Interest Earned fell 718.24% to -$6.81 in Q3 2025 from the same period last year, while for Sep 2025 it was $16.11, marking a year-over-year increase of 61732.2%. This contributed to the annual value of -$25.98 for FY2024, which is 55146.27% down from last year.
  • Per Autolus Therapeutics' latest filing, its Times Interest Earned stood at -$6.81 for Q3 2025, which was down 718.24% from $8.96 recorded in Q2 2025.
  • Autolus Therapeutics' Times Interest Earned's 5-year high stood at $8.96 during Q2 2025, with a 5-year trough of -$21.58 in Q2 2022.
  • For the 5-year period, Autolus Therapeutics' Times Interest Earned averaged around -$8.09, with its median value being -$6.62 (2025).
  • Data for Autolus Therapeutics' Times Interest Earned shows a peak YoY increase of 25476.67% (in 2025) and a maximum YoY decrease of 21978.39% (in 2025) over the last 5 years.
  • Over the past 5 years, Autolus Therapeutics' Times Interest Earned (Quarter) stood at -$20.9 in 2021, then soared by 83.88% to -$3.37 in 2022, then surged by 47.53% to -$1.77 in 2023, then surged by 239.15% to $2.46 in 2024, then plummeted by 376.72% to -$6.81 in 2025.
  • Its Times Interest Earned was -$6.81 in Q3 2025, compared to $8.96 in Q2 2025 and -$6.43 in Q1 2025.